Cancer, a disease which has tormented many people. The disease is considered to account for approximately one-third of deaths worldwide even now. Anticancer agents in chemotherapy are most frequently used to treat cancer. Anticancer agents try to heal cancer patients by destroying cancer cells but simultaneously provoke various adverse reactions because they affect normal cells as well. Under current medications, these adverse reactions continue to jeopardize the QOL (Quality of Life) of patients with cancer.
With an aim to solve these problems and to recuperate the QOL of cancer patients, NanoCarrier Co., Ltd. was established by the encounter of two leading experts in the field of biomaterials, Professor Kazunori Kataoka, Graduate School of Engineering at the University of Tokyo, and Professor Mitsuo Okano, Institute of Biomedical Engineering at Tokyo Women's Medical University, with Ichiro Nakatomi, Ph.D., the president and CEO of NanoCarrier who has succeeded in a pharmaceutical venture in the U.S.
We are engaged in the research and development of drugs in which the world's most advanced nanotechnology and drug delivery system (DDS) technology are fused together. We synthesize ultrafine particles (20-100 nm) of nanometer size that are much smaller than viruses and incorporate drugs, e.g., anticancer agents, into them to allow the more efficacious exertion of their pharmacological effects in the body. We aim to develop novel formulations which can achieve "increase in pharmacological actions" and "reduction in adverse reactions" that were impossible to be realized with conventional mediations.
We are challenging to demolish the current status in which the concept of "Anticancer agents necessarily provoke adverse reactions." has nearly become common knowledge.